Clinical Trial: Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07596290) titled 'Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC' on May 10.

Brief Summary: This is a prospective, multicenter, randomized controlled trial aimed at comparing different radiotherapy fractionation regimens combined with sequential dual immunotherapy versus traditional chemoradiotherapy in neoadjuvant treatment for locally advanced rectal cancer (LARC). A total of 342 pMMR/MSS LARC patients will be enrolled and randomly assigned in a 1:1:1 ratio to short-course radiotherapy (5x5Gy) followed by sequential dual immunotherapy (paromlimab + tuvonralimab + CAPEOX), long-course radiotherapy followed by sequential dual immunotherapy, ...